Clinical Trials

16 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma

NCT05901519 2026-03-13

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06124157 2026-03-13

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

75 enrolled

Prostatic Neoplasms

NCT06353386 2026-03-13

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06717347 2026-03-13

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06925737 2026-03-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07225946 2026-03-13

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06043323 2026-03-12

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

20 enrolled

Lymphoma, Follicular

NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

800 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06136624 2026-03-11

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT07005154 2026-03-03

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06457919 2026-02-19

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT07339267 2026-02-18

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

12 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

277 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06564038 2026-02-05

Soundtrack-E

276 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

174 enrolled

Lymphoma, B-Cell

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT06470243 2026-01-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

528 enrolled

Prostatic Neoplasms

NCT04633252 2026-01-16

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

86 enrolled

Prostatic Neoplasms

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

160 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

32 enrolled

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

260 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

100 enrolled

Prostate Adenocarcinoma

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

35 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02960022 2025-12-17

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

53 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03833921 2025-12-11

APRE

130 enrolled

Prostatic Neoplasms

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled